|LETTERS TO EDITOR
|Year : 2017 | Volume
| Issue : 5 | Page : 491-492
Clinicomicrobiological study of community-acquired pneumonia
Prashasti Prasad1, Sevitha Bhat2
1 Final MBBS Student, Kasturba Medical College, Mangalore, Karnataka, India
2 Department of Microbiology, Kasturba Medical College, Mangalore, Karnataka, India
|Date of Web Publication||31-Aug-2017|
Department of Microbiology, Kasturba Medical College, Mangalore, Karnataka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Prasad P, Bhat S. Clinicomicrobiological study of community-acquired pneumonia. Lung India 2017;34:491-2
Community-acquired pneumonia (CAP) remains as an infectious cause of mortality and morbidity globally. The common etiological agents of CAP are Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, and Pseudomonas aeruginosa. Pneumonia is reported more in older patients and those with comorbidities, such as chronic liver, cardiac, lung and/or renal diseases, metabolic disorders such as diabetes mellitus, chronic alcoholism, malignancies, absence of spleen (asplenia), immune-compromising conditions or the use of immune-suppressing drugs, exposure to radiation or chemotherapy, and administration of antimicrobials, within the previous 3 months. In India, the incidence of CAP is 4 million cases/year with 20% requiring hospitalization. The mortality rate of CAP patients in outpatient settings is 1%–5%, and in Intensive Care Unit, it is 25%.,
CAP is treated using either monotherapy or combination therapy. Doxycycline and respiratory quinolones are preferred as single agents. Combination therapy includes ceftriaxone plus doxycycline or azithromycin.
Antibiotic resistance is on rise among the respiratory pathogens. The incidence of β-lactamase production has been reported in 20%–35% of the isolates of H. influenzae. Macrolide resistance has been reported as 5% while previous studies have reported a low prevalence rate of 0.15% resistance to fluoroquinolones.
The present study was undertaken to study the pattern of antibiotic resistance in respiratory isolates and the associated risk factors of CAP. A cross-sectional study was carried out in the tertiary care center. A total of 165 patients of the age 16 years and above with clinical suspicion of CAP were included in the study. Respiratory tract specimen, bronchoalveolar lavage samples, and sputum samples with the growth of bacterial pathogens were included in the study. The samples were plated on chocolate agar and blood agar and MacConkey agar and incubated at 37°C overnight, and any bacterial growth was identified by the standard biochemical reactions and the antibiotic sensitivity done by modified Kirby-Bauer disk diffusion method.
The mean age of the patients was found to be 58 years. A total of 104 (63.6%) were male and 61 (36%) female. After the treatment course was completed, 124 were successfully cured, 4 patients died, and 37 developed reinfection (within the next 60 days). The common bacterial pathogens found to be responsible for CAP in our study were K. pneumoniae (29.09%), H. influenzae (4.8%), Pseudomonas spp.(18.18%), and S. pneumoniae (13.33%).
The culture positivity rate in our study was 48%. The remaining culture negative cases who presented to our hospital could be due to prior antibiotic administration, atypical bacterial pathogens, or viruses. The patients in this study presented with fever (93%), cough with sputum (94%), and chest pain (60%). The risk factors of CAP in our study were diabetes mellitus, alcohol/tobacco use, bronchiectasis, cancer patients, and elderly, similar to previous reports. The antibiotics effective against S. pneumoniae were amoxiclav, levofloxacin with around 20% resistance. The antibiotics against H. influenzae were cefuroxime, azithromycin, and amoxiclav with 6%, 13%, and 23% resistance, respectively. The antibiotics effective against K. pneumoniae, Pseudomonas spp. were carbapenems, piperacillin-tazobactam, and cefoperazone-sulbactam, with their resistance percentages being relatively less at 16.6%, 39.5%, and 42%, respectively.
The study has received ICMR-STS grant: 2016. The authors are grateful to Manipal University for all the support.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Shah BA, Singh G, Naik MA, Dhobi GN. Bacteriological and clinical profile of community acquired pneumonia in hospitalized patients. Lung India 2010;27:54-7.
] [Full text]
American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am J Respir Crit Care Med 2001;163:1730-54.
Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004;38 Suppl 4:S328-40.
Chawla K, Mukhopadhay C, Majumdar M, Bairy I. Bacteriological profile and their antibiogram from cases of acute exacerbations of chronic obstructive pulmonary disease: A hospital based study. J Clin Diagn Res 2008;2:612-6.